Prevalence and characteristics of adverse drug reaction prospective observational study

British Journal of Clinical Pharmacology 82, 1636-1646

DOI: 10.1111/bcp.13081

Citation Report

#	ARTICLE	IF	Citations
1	Prevalence and characteristics of adverse drug reactions at admission to hospital: a prospective observational study. British Journal of Clinical Pharmacology, 2016, 82, 1636-1646.	1.1	67
3	Role of Medicines of Unknown Identity in Adverse Drug Reaction-Related Hospitalizations in Developing Countries: Evidence from a Cross-Sectional Study in a Teaching Hospital in the Lao People's Democratic Republic. Drug Safety, 2017, 40, 809-821.	1.4	9
4	HLA-associated drug hypersensitivity and the prediction of adverse drug reactions. Pharmacogenomics, 2017, 18, 1441-1457.	0.6	29
5	Early rehospitalizations of frail elderly patients & Description of medications: a clinical, prospective, observational trial. Drug, Healthcare and Patient Safety, 2017, Volume 9, 77-88.	1.0	17
6	Preventable ADRs leading to hospitalization â€" results of a long-term prospective safety study with 6,427 ADR cases focusing on elderly patients. Expert Opinion on Drug Safety, 2018, 17, 125-137.	1.0	33
7	Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis. European Journal of Clinical Pharmacology, 2018, 74, 819-832.	0.8	48
8	Pharmacist-initiated deprescribing in hospitalised elderly: prevalence and acceptance by physicians. European Journal of Hospital Pharmacy, 2018, 25, e35-e39.	0.5	14
9	Which drugs cause treatment-related problems? Analysis of 10,672 problems within the outpatient setting. Therapeutics and Clinical Risk Management, 2018, Volume 14, 2273-2281.	0.9	3
10	Benefits and risks of the treatment with fibrates––a comprehensive summary. Expert Review of Clinical Pharmacology, 2018, 11, 1099-1112.	1,3	34
11	LC–MS/MS assay for assessing medical adherence in patients under warfarin maintenance therapy. Microchemical Journal, 2018, 141, 135-140.	2.3	4
12	Minimum Information Required for Pharmacogenomics Experiments. , 2018, , 179-193.		0
13	Development of a mortality score to assess risk of adverse drug reactions among hospitalized patients with moderate to severe chronic kidney disease. BMC Pharmacology & Empty Toxicology, 2019, 20, 41.	1.0	4
15	Detecting adverse drug reactions in discharge summaries of electronic medical records using Readpeer. International Journal of Medical Informatics, 2019, 128, 62-70.	1.6	18
16	Implementation and obstacles of pharmacogenetics in clinical practice: An international survey. British Journal of Clinical Pharmacology, 2019, 85, 2076-2088.	1.1	30
17	Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adults. Pharmacogenomics Journal, 2019, 19, 401-410.	0.9	15
18	Effects of the number of drugs used on the prevalence of adverse drug reactions in children. Scientific Reports, 2020, 10, 21341.	1.6	14
19	Clinical usefulness of genetic testing for drug toxicity in cancer care: decision-makers' framing, knowledge and perceptions. New Genetics and Society, 2020, 39, 359-384.	0.7	0
20	Adverse Drug Reactions in Patients with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1090-1102.	2.2	47

#	Article	IF	CITATIONS
21	The characteristics and regularities of cardiac adverse drug reactions induced by Chinese materia medica: A bibliometric research and association rules analysis. Journal of Ethnopharmacology, 2020, 252, 112582.	2.0	9
22	Protocol for a randomised controlled trial evaluating the impact of a community pharmacy discharge medication reconciliation service on unplanned hospital readmissions – The DCMedsRec trial. Research in Social and Administrative Pharmacy, 2021, 17, 460-465.	1.5	0
23	Cohort study on adverse drug reactions in adults admitted to the medical wards of a tertiary hospital in Nigeria: Prevalence, incidence, risk factors and fatality. British Journal of Clinical Pharmacology, 2021, 87, 1878-1889.	1.1	8
24	Fenofibrate treatment for severe hypertriglyceridemia in dogs. Domestic Animal Endocrinology, 2021, 74, 106578.	0.8	10
25	Prescription patterns of outpatients and the potential of multiplexed pharmacogenomic testing. British Journal of Clinical Pharmacology, 2021, 87, 886-894.	1.1	3
26	Modeling the Bioactivation and Subsequent Reactivity of Drugs. Chemical Research in Toxicology, 2021, 34, 584-600.	1.7	11
27	Adverse reactions of targeted therapy in cancer patients: a retrospective study of hospital medical data in China. BMC Cancer, 2021, 21, 206.	1.1	19
28	Calycosin Induces Gastric Cancer Cell Apoptosis via the ROS-Mediated MAPK/STAT3/NF-κB Pathway. OncoTargets and Therapy, 2021, Volume 14, 2505-2517.	1.0	11
30	Pharmacogenomics Implementation Training Improves Self-Efficacy and Competency to Drive Adoption in Clinical Practice. Frontiers in Pharmacology, 2021, 12, 684907.	1.6	3
31	Predictors of Medication-Related Emergency Department Admissions Among Patients with Cardiovascular Diseases at Mbarara Regional Referral Hospital, South-Western Uganda. Open Access Emergency Medicine, 2021, Volume 13, 279-290.	0.6	1
32	Controlling drug release with additive manufacturing-based solutions. Advanced Drug Delivery Reviews, 2021, 174, 369-386.	6.6	33
33	Adverse Drug Reactions in Selected Wards of the Yangon General Hospital and Yangon Specialty Hospital During the First Quarter of 2019: An Active Pharmacovigilance Study in Myanmar. Drugs - Real World Outcomes, 2020, 7, 109-117.	0.7	1
34	Drug-related deaths among inpatients: a meta-analysis. European Journal of Clinical Pharmacology, 2022, 78, 267-278.	0.8	6
35	Validation of a multi-gene qPCR-based pharmacogenomics panel across major ethnic groups in Singapore and Indonesia. Pharmacogenomics, 2021, 22, 1041-1056.	0.6	1
36	Comparative Analysis of Ethical-the-counter Drugs and Over-the-counter Drugs for the Adverse Events from the Community Pharmacy. Korean Journal of Clinical Pharmacy, 2018, 28, 230-237.	0.0	0
37	Hospitalizations and deaths related to adverse drug events worldwide: Systematic review of studies with national coverage. European Journal of Clinical Pharmacology, 2022, 78, 435-466.	0.8	13
38	A Retrospective Descriptive Study of Adverse Drug Reaction Monitoring in Tertiary Care Hospital. Journal of Medical Academics, 2021, 3, 54-58.	0.1	0
39	Hubungan Tingkat Kejadian Efek Samping Antiinflamasi Non Steroid dengan Usia dan Jenis Kelamin. Jurnal Farmasi Dan Ilmu Kefarmasian Indonesia, 2020, 6, 56.	0.0	4

3

#	Article	IF	CITATIONS
41	Ten-year trends in adverse drug reaction–related hospitalizations among people with dementia. Therapeutic Advances in Drug Safety, 2022, 13, 204209862210807.	1.0	4
42	Student assistantship programme: an evaluation of impact on readiness to transit from medical student to junior doctor. BMC Medical Education, 2022, 22, 99.	1.0	3
43	Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions. International Journal of Molecular Sciences, 2021, 22, 13302.	1.8	25
44	IT Solutions for Preventing and Monitoring Adverse Drug Reactions: A Systematic Literature Review. , 2021, , .		0
45	Budget impact analysis of a pilot polypharmacy clinic. British Journal of Health Care Management, 2022, 28, 1-9.	0.1	0
46	Incidence of adverse drug events in patients hospitalized in the medical wards of a teaching referral hospital in Ethiopia: a prospective observational study. BMC Pharmacology & Education (2022), 23, 30.	1.0	6
47	Therapy for feline secondary hypertriglyceridemia with fenofibrate. Journal of Feline Medicine and Surgery, 2022, 24, e251-e257.	0.6	1
48	A novel machine learning model based on sparse structure learning with adaptive graph regularization for predicting drug side effects. Journal of Biomedical Informatics, 2022, 132, 104131.	2.5	3
49	Experience of patients with lung cancer and with targeted therapy-related skin adverse drug reactions: A qualitative study. Asia-Pacific Journal of Oncology Nursing, 2022, 9, 100115.	0.7	2
50	Calycosin Inhibits the Malignant Behaviors of Lung Adenocarcinoma Cells by Regulating the circ_0001946/miR-21/GPD1L/HIF-1 $\hat{l}$ ± Signaling Axis. Disease Markers, 2022, 2022, 1-18.	0.6	3
51	Pharmacogenomics of Alzheimer's Disease: Novel Strategies for Drug Utilization and Development. Methods in Molecular Biology, 2022, , 275-387.	0.4	4
52	Pharmacists' experiences on adverse drug reaction: 10Âyears later. Frontiers in Pharmacology, 0, 13, .	1.6	1
53	Individual Pharmacotherapy Management (IPM)â€"IV: Optimized Usage of Approved Antimicrobials Addressing Under-Recognized Adverse Drug Reactions and Drug-Drug Interactions in Polypharmacy. Antibiotics, 2022, 11, 1381.	1.5	2
54	Improving prescribing: a feasibility study of pharmacogenetic testing with clinical decision support in primary healthcare in Singapore. Family Practice, 0, , .	0.8	1
55	Utilization of Drug Decision Support Strategies Including Drug Characteristics to Reduce the Risk of latrogenesis in Advanced Age. Current Pharmacology Reports, 2023, 9, 32-42.	1.5	1
56	Editorial: Medication safety and interventions to reduce patient harm in low- and middle-income countries. Frontiers in Pharmacology, $0,13,.$	1.6	0
57	Which Adverse Events and Which Drugs Are Implicated in Drug-Related Hospital Admissions? A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2023, 12, 1320.	1.0	3
58	Severity and Management of Adverse Drug Reactions Reported by Patients and Healthcare Professionals: A Cross-Sectional Survey. International Journal of Environmental Research and Public Health, 2023, 20, 3725.	1.2	1

#	Article	IF	CITATIONS
59	Incidence and patterns of adverse drug reactions among adult patients hospitalized in the University of Gondar comprehensive specialized hospital: A prospective observational follow-up study. PLoS ONE, 2023, 18, e0282096.	1.1	3
64	Applications of "Omics―Sciences in the Laboratory. , 2023, , 683-691.		O